Increasing numbers of men are being diagnosed with prostate cancer and undergo operative curative treatment. It has been suggested that outcome after radical prostatectomy (RP) may vary for different age groups. Objective: To investigate whether PSA recurrence-free survival after RP is related to age at operation for a cohort of English men. Methods: A total of 854 patients notes from four Urology units were audited for preoperative staging parameters and follow-up data obtained. The relationship of PSA, age, biopsy Gleason grade, clinical stage, era and institution on PSA recurrence-free survival was competitively assessed with a multivariate model. Results: Only preoperative PSA (Po0.0001) and biopsy Gleason grade (Po0.0001) were found to be strongly associated with PSA recurrence-free survival on multivariate analysis. PSA recurrence-free survival probabilities at 5 y for patients respectively. No significant difference of PSA recurrence-free survival between any of the age groups was found (Log-rank, P ¼ 0.8567). Conclusion: No significant difference of pathological variables or biochemical recurrence across the age groups was found. The widely held belief of poorer outcome in younger men selected for RP does not seem to be borne out by this study.
Introduction
It is well recognised that increasing age is a risk factor for the development of prostate cancer. 1 With the advent of widespread PSA testing and greater public awareness, increasing numbers of men are being diagnosed with prostate cancer and selected for curative treatment. The age profile of men undergoing radical prostatectomy (RP) has changed over the last 20 y and the median age has dropped. In the early 1980's young men less than 50 y of age constituted 1% of all prostate cancers, 2 but more recently this has risen to approximately 4%. 3 Previously, it was believed there may be a difference in outcome for men of different ages with younger men faring worse from biochemical failure and survival compared to their older counterparts. This was without clear supportive evidence and was in part due to the belief that younger patients had advanced aggressive disease at presentation, possibly related to altered tumour biology and genetics. With opportunistic PSA screening, tumours are found earlier today resulting in a significant downward stage migration across all age ranges. 4 Recent studies have also shown that in particular, men younger than 50 y have a lower incidence of extracapsular extension, seminal vesicle involvement and greater incidence of organ-confined disease compared to older patients in the United States. 5 This is in keeping with results from other studies which have suggested that younger patients fare better following RP.
6-8 On the contrary, age does not feature significantly on multivariate Cox proportional hazards analysis when identifying contemporary patients at high risk of early prostate cancer recurrence after RP. 9 Khan et al 5 recently demonstrated that older patients 470 y of age had worse biochemical-free survival rates over a 15-y-follow-up period compared to a younger cohort of patients.
In view of these contradictory findings we present a multicentre study to investigate whether outcome after RP is related to age at operation for a cohort of English men.
Methods
In all, 854 patients notes from four Urology units (two academic units and two District General Hospitals) were audited for preoperative staging parameters and followup data obtained. From 1997 all units had at least a yearly through put of 20 RPs. Data were collected retrospectively. From 1998 onwards, databases were continuously updated. In all, 704 patients underwent radical retropubic prostatectomy and 150 patients underwent radical perineal prostatectomy. Patients excluded from the multivariate analysis included 84 patients who received neoadjuvant therapy and 36 patients who received adjuvant treatment prior to PSA recurrence. The influence of neoadjuvant and adjuvant treatment on survival is unknown and can distort a multivariate analysis. A further 52 patients with incomplete data were excluded. The remaining 682 patients were submitted to a multivariate analysis (Cox proportional hazards regression) to identify preoperative factors (age, PSA, biopsy Gleason score, clinical stage) associated with biochemical recurrence in the first 5 y following RP. Since patients were recruited over a long period of time from four different urology units, it was thought that other factors such as the year and place (institution) of operation could have an influence on outcome. These factors were therefore competitively assessed in the multivariate model. Probability estimates of recurrencefree survival were calculated with the Kaplan-Meier method. Log-rank test was used to compare KaplanMeier survival curves. The preoperative PSA was recorded prior to any intervention, that is, DRE, biopsy or TURP. Biochemical recurrence was defined as at least two consecutive elevations above a PSA of 0.2 ng/ml. A positive surgical margin was defined as prostatic adenocarcinoma at the inked margin of the pathological specimen regardless as to the location or extent of the margin and carcinoma involved. Staging followed the 1997 TNM classification.
Results
The median prebiopsy PSA of all 682 patients was 9.7 ng/ml (mean 11.7 ng/ml) and the median age was 64 y (Table 1) . Of the 682 patients only 7% were o55 y and 13% 470 y of age ( Table 1 ). The remainder of the descriptive statistics including number of operation per institution, operations per year, preoperative and postoperative grade and stage distribution are shown in Table 1 . There was a significant upgrading of 40% (Table 1) . Table 2 shows the distribution of preoperative PSA and postoperative stage across the age ranges. The group of young patients (45-55 y) showed a trend towards lower PSA albeit not statistically significant (P ¼ 0.182). Likewise, from Table 2 it appears that this group has a slightly more favourable pathological stage distribution and lower positive margin rates. However, these differences were not statistically significant (P ¼ 0.1703 and 0.1378, respectively).
In all, 184 patients showed evidence of PSA recurrence and the medium time to PSA recurrence was 10. Only pre-operative PSA (Po0.0001) and biopsy Gleason grade (Po0.0001) were found to be strongly associated with PSA recurrence-free survival on multi- (Table 3) . PSA recurrence free survival probabilities at 5 y for patients aged 45-55 y, 55. Figure 1 . No significant difference of PSA recurrence-free survival between any of the age groups was found (Log-rank, P ¼ 0.8567).
Discussion
Recently, there have been a few reports comparing the outcome of men undergoing RP to ascertain whether there is a difference in the rate of organ-confined disease, margin status and PSA recurrence-free survival between different age groups. However, there is no available data to date, assessing the outcome according to age groups in a UK population. We know that outcome after RP in the UK is less optimistic compared to the often quoted large American series of RP. 4, 10, 11 This multicentre study assesses whether the age of English men undergoing RP is related to outcome (PSA recurrence-free survival). Such information would allow clinicians to counsel and select suitable candidates for RP irrespective of age.
In this study, we found that the younger cohort of patients had a trend towards lower preoperative PSA in keeping with other studies (Table 2) . 5, 12 More young men (45-55 y) had a PSA under 4 ng/ml than old men (70.1-75 y): 15 vs 6%, respectively. However, this difference was not significant (P ¼ 0.182). Previous reports 5,6,12,13 have shown that a lower PSA at presentation in young men is PSA recurrence following radical prostatectomy FA Khan et al associated with a greater rate of organ-confined disease and subsequently a better long-term biochemical freedom from recurrence up to 15 y after RP. This finding has been used to support a potential role for using age specific PSA first suggested by Oesterling et al 14 in specifically screening a younger cohort of patients or those at particular risk of prostate cancer. 15, 16 Although the younger patients showed a trend towards lower PSA, this study did not show any significant difference in the rate of nonorgan-confined disease and margin status between the separate age groups. Despite a trend towards more organ-confined disease for younger men, there was no difference in the 5-y PSA-free survival rates for all the age groups, which is contrary to the findings of the larger US-based study. 5 Significant differences in the pathological variables were only noted between the o50-y and 60-69 y and 470-y old groups, with the youngest group showing the most favourable features. Comparing the biochemical disease-free survival only showed a significant difference between the o50 y and 470 y old groups. 5 Despite the more favourable pathology in the o50 y group, this did not translate to a significant PSAfree survival advantage compared to the 60-69 y group. 5 We chose to analyse age competitively with all other preoperative parameters (including era and institution) on multivariate analysis to allow for a meaningful assessment of this parameter in relation to other factors. Our results did show a similarity both in the pathological status and PSA-free survival across the age range. This is important for two reasons; firstly it suggests that prostate cancer in young men undergoing radical prostatectomy is probably no worse than disease found in the older patient, contrary to earlier beliefs. 2, 17, 18 Secondly, it may support the claim that there is no difference in outcome following radical surgery across all age ranges. It also shows that older men in the UK do not have significantly more advanced disease compared to their younger counterparts, and that they do just as well after radical surgery with regards to biochemical recurrence. The time of operation (era) and place of operation (institution) were both not significant on multivariate analysis. This indicates that our multicentre cohort of patient was reasonably homogenous to allow a meaningful analysis. The median follow-up is only 48 months and the conclusions drawn might well change after a longer follow-up period.
Our results are similar to those reported in studies comparing the PSA outcomes in patients of different ages treated with external beam radiotherapy (EBRT). 19, 20 The difference in biochemical outcome seen between this study, and the EBRT studies, which show no age-related advantage and the US-based studies, 7, 9 which show a better outcome in younger men may, in part, be due to a treatment selection bias in the latter studies. Younger men are generally more likely to be offered radical surgery. Elderly patients, however, are less likely to be offered radical surgery, and even suitable patients with low-volume organ-confined disease are more likely to be managed with watchful waiting. In addition, penetration of PSA screening is 50-70% in the US and 3-5% in England. This leads to a situation where older men selected for radical surgery are more likely to have higher volume disease compared to their younger counterparts, and this in turn may have caused a reduced PSA-free survival in such studies. This selection bias was also reported in a recent study investigating practice among Urologists in Ontario, Canada. 21 Alibhai et al found that older men with localised prostate cancer were treated less often with radical prostatectomy than younger men, despite patients in both groups having a similar 'relative life expectancy' based on their age, comorbidity and tumour stage. Their study highlighted the inherent 'ageism' which leads to bias when counselling for suitable treatment options for localised disease. The similarity in outcome between the age groups may be the result of a reduced treatment selection bias among clinicians in England.
Conclusion
No significant difference of pathological variables or biochemical recurrence across the age groups was found. Performance status of the patient and relative life expectancy independent of age would be of greater significance to case selection. The widely held belief of more aggressive disease and poorer outcome in younger men does not seem to be borne out by this study.
